screen_file
string | organism
string | perturbation
string | gene
string | cell
string | phenotype
string | hit
int64 | benchmark_type
string | prompt
string | gene_context
string |
|---|---|---|---|---|---|---|---|---|---|
SCREEN_17_HITS_ONLY_FOR_INVERSE.tsv
|
mouse
|
knockout
|
Rps6
|
3LL Lewis lung carcinoma cells
|
decreased resistance to PD1 blockade and lung carcinoma cell death
| 0
|
difficult
|
Does knockout of Rps6 in 3LL Lewis lung carcinoma cells causally result in decreased resistance to PD1 blockade and lung carcinoma cell death?
|
Gene: Rps6 (ribosomal protein S6)
Type: protein-coding
Summary: No summary available.
Gene Ontology: BP: G1/S transition of mitotic cell cycle, T cell differentiation in thymus, T cell proliferation involved in immune response, TOR signaling, activation-induced cell death of T cells, cellular response to ethanol, cytoplasmic translation, erythrocyte development, gastrulation, glucose homeostasis, mammalian oogenesis stage, mitotic cell cycle, negative regulation of apoptotic process, negative regulation of bicellular tight junction assembly, placenta development, positive regulation of apoptotic process, positive regulation of cell population proliferation, rRNA processing, response to insulin, ribosomal small subunit assembly, ribosomal small subunit biogenesis, ribosome biogenesis, translation; MF: mRNA binding, protein binding, protein kinase binding, structural constituent of ribosome; CC: GABA-ergic synapse, cell body, cytoplasm, cytoplasmic ribonucleoprotein granule, cytosol, cytosolic ribosome, cytosolic small ribosomal subunit, dendrite, endoplasmic reticulum, nucleolus, nucleus, perinuclear region of cytoplasm, presynapse, ribonucleoprotein complex, ribosome, small ribosomal subunit, small-subunit processome
Pathways: Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S, Apelin signaling pathway - Mus musculus (mouse), Cap-dependent Translation Initiation, Coronavirus disease - COVID-19 - Mus musculus (mouse), Eukaryotic Translation Initiation, Formation of a pool of free 40S subunits, Formation of the ternary complex, and subsequently, the 43S complex, GTP hydrolysis and joining of the 60S ribosomal subunit, Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation, HIF-1 signaling pathway - Mus musculus (mouse), Insulin signaling pathway - Mus musculus (mouse), L13a-mediated translational silencing of Ceruloplasmin expression, MTOR signalling, Major pathway of rRNA processing in the nucleolus and cytosol, Metabolism of RNA, Metabolism of proteins, Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC), Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC), Nonsense-Mediated Decay (NMD), PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA, PI3K-Akt signaling pathway - Mus musculus (mouse), Post-translational protein modification, Protein hydroxylation, Proteoglycans in cancer - Mus musculus (mouse), Ribosomal scanning and start codon recognition, Ribosome - Mus musculus (mouse), Ribosome-associated quality control, SRP-dependent cotranslational protein targeting to membrane, Signal Transduction, Thermogenesis - Mus musculus (mouse), Translation, Translation initiation complex formation, ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA, mTOR signaling pathway - Mus musculus (mouse), mTORC1-mediated signalling, rRNA processing, rRNA processing in the nucleus and cytosol
UniProt: P62754
Entrez ID: 20104
|
SCREEN_17_HITS_ONLY_FOR_INVERSE.tsv
|
mouse
|
knockout
|
Men1
|
3LL Lewis lung carcinoma cells
|
decreased resistance to PD1 blockade and lung carcinoma cell death
| 0
|
difficult
|
Does knockout of Men1 in 3LL Lewis lung carcinoma cells causally result in decreased resistance to PD1 blockade and lung carcinoma cell death?
|
Gene: Men1 (multiple endocrine neoplasia 1)
Type: protein-coding
Summary: No summary available.
Gene Ontology: BP: DNA damage response, MAPK cascade, T-helper 2 cell differentiation, chromatin organization, chromatin remodeling, embryonic skeletal system morphogenesis, hemopoiesis, leukocyte homeostasis, maternal process involved in female pregnancy, negative regulation of DNA-templated transcription, negative regulation of JNK cascade, negative regulation of cell cycle, negative regulation of cell cycle G1/S phase transition, negative regulation of cell population proliferation, negative regulation of cell-substrate adhesion, negative regulation of epithelial cell proliferation, negative regulation of fibroblast proliferation, negative regulation of organ growth, negative regulation of osteoblast differentiation, negative regulation of stem cell proliferation, negative regulation of transcription by RNA polymerase II, negative regulation of type B pancreatic cell proliferation, ossification, osteoblast development, osteoblast fate commitment, positive regulation of DNA-templated transcription, positive regulation of cell division, positive regulation of fibroblast apoptotic process, positive regulation of gene expression, positive regulation of osteoblast differentiation, positive regulation of stem cell differentiation, positive regulation of transcription by RNA polymerase II, positive regulation of transforming growth factor beta receptor signaling pathway, regulation of G1/S transition of mitotic cell cycle, regulation of activin receptor signaling pathway, regulation of gene expression, regulation of transcription by RNA polymerase II, regulation of type B pancreatic cell proliferation, response to UV, response to gamma radiation, response to transforming growth factor beta, roof of mouth development, transcription initiation-coupled chromatin remodeling, type B pancreatic cell differentiation; MF: DNA binding, DNA-binding transcription activator activity, R-SMAD binding, Y-form DNA binding, chromatin binding, double-stranded DNA binding, four-way junction DNA binding, phosphoprotein binding, protein binding, protein-macromolecule adaptor activity, sequence-specific DNA binding, transcription cis-regulatory region binding; CC: MLL1 complex, MLL1/2 complex, chromatin, chromosome, telomeric region, cleavage furrow, cytoplasm, cytosol, histone methyltransferase complex, nuclear matrix, nucleoplasm, nucleus, protein-containing complex, transcription repressor complex
Pathways: Cushing syndrome - Mus musculus (mouse), Epigenetic regulation by WDR5-containing histone modifying complexes, Epigenetic regulation of gene expression, Formation of WDR5-containing histone-modifying complexes, Formation of the beta-catenin:TCF transactivating complex, Gene expression (Transcription), Generic Transcription Pathway, Metabolism of proteins, Post-translational protein modification, Post-translational protein phosphorylation, RHO GTPase Effectors, RHO GTPases activate IQGAPs, RNA Polymerase II Transcription, Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs), SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription, Signal Transduction, Signaling by Rho GTPases, Signaling by Rho GTPases, Miro GTPases and RHOBTB3, Signaling by TGF-beta Receptor Complex, Signaling by TGFB family members, Signaling by WNT, TCF dependent signaling in response to WNT, Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer, Transcriptional misregulation in cancer - Mus musculus (mouse)
UniProt: O88559
Entrez ID: 17283
|
SCREEN_17_HITS_ONLY_FOR_INVERSE.tsv
|
mouse
|
knockout
|
Cd47
|
3LL Lewis lung carcinoma cells
|
decreased resistance to PD1 blockade and lung carcinoma cell death
| 0
|
difficult
|
Does knockout of Cd47 in 3LL Lewis lung carcinoma cells causally result in decreased resistance to PD1 blockade and lung carcinoma cell death?
|
Gene: Cd47 (CD47 antigen (Rh-related antigen, integrin-associated signal transducer))
Type: protein-coding
Summary: No summary available.
Gene Ontology: BP: ATP export, angiogenesis, apoptotic process, cell adhesion, cell migration, cell-cell adhesion, cellular response to interleukin-1, cellular response to interleukin-12, cellular response to type II interferon, inflammatory response, monocyte aggregation, negative regulation of phagocytosis, opsonization, positive regulation of T cell activation, positive regulation of activation-induced cell death of T cells, positive regulation of cell population proliferation, positive regulation of cell-cell adhesion, positive regulation of immune system process, positive regulation of inflammatory response, positive regulation of monocyte extravasation, positive regulation of phagocytosis, positive regulation of stress fiber assembly, regulation of Fc receptor mediated stimulatory signaling pathway, regulation of interleukin-10 production, regulation of interleukin-12 production, regulation of interleukin-6 production, regulation of nitric oxide biosynthetic process, regulation of synapse pruning, regulation of tumor necrosis factor production, regulation of type II interferon production, response to bacterium; MF: cell-cell adhesion mediator activity, fibrinogen binding, protein binding, protein binding involved in heterotypic cell-cell adhesion, thrombospondin receptor activity; CC: cell surface, extracellular exosome, glutamatergic synapse, membrane, plasma membrane, presynapse
Pathways: Cell surface interactions at the vascular wall, Cell-Cell communication, ECM-receptor interaction - Mus musculus (mouse), Extracellular matrix organization, Hemostasis, Immune System, Innate Immune System, Integrin cell surface interactions, Neutrophil degranulation, Signal regulatory protein family interactions
UniProt: Q61735
Entrez ID: 16423
|
SCREEN_17_HITS_ONLY_FOR_INVERSE.tsv
|
mouse
|
knockout
|
Asxl1
|
3LL Lewis lung carcinoma cells
|
decreased resistance to PD1 blockade and lung carcinoma cell death
| 0
|
difficult
|
Does knockout of Asxl1 in 3LL Lewis lung carcinoma cells causally result in decreased resistance to PD1 blockade and lung carcinoma cell death?
|
Gene: Asxl1 (ASXL transcriptional regulator 1)
Type: protein-coding
Summary: No summary available.
Gene Ontology: BP: animal organ morphogenesis, bone development, bone marrow development, cell morphogenesis, chromatin organization, heart morphogenesis, hematopoietic or lymphoid organ development, hemopoiesis, homeostasis of number of cells, lung saccule development, negative regulation of fat cell differentiation, negative regulation of lipid storage, negative regulation of peroxisome proliferator activated receptor signaling pathway, podocyte development, positive regulation of retinoic acid receptor signaling pathway, positive regulation of transcription by RNA polymerase II, regulation of DNA-templated transcription, regulation of kidney size, response to retinoic acid, thymus development; MF: DNA binding, chromatin binding, metal ion binding, nuclear retinoic acid receptor binding, peroxisome proliferator activated receptor binding, protein binding, transcription coactivator activity, zinc ion binding; CC: PR-DUB complex, nucleus
Pathways: Deubiquitination, Metabolism of proteins, Post-translational protein modification, UCH proteinases
UniProt: P59598
Entrez ID: 228790
|
SCREEN_17_HITS_ONLY_FOR_INVERSE.tsv
|
mouse
|
knockout
|
Sufu
|
3LL Lewis lung carcinoma cells
|
decreased resistance to PD1 blockade and lung carcinoma cell death
| 0
|
difficult
|
Does knockout of Sufu in 3LL Lewis lung carcinoma cells causally result in decreased resistance to PD1 blockade and lung carcinoma cell death?
|
Gene: Sufu (SUFU negative regulator of hedgehog signaling)
Type: protein-coding
Summary: No summary available.
Gene Ontology: BP: aorta development, coronary vasculature development, determination of left/right symmetry, dorsal/ventral neural tube patterning, heart looping, maintenance of protein localization in organelle, negative regulation of smoothened signaling pathway, negative regulation of transcription by RNA polymerase II, negative regulation of ubiquitin-dependent protein catabolic process, neural tube closure, positive regulation of cellular response to drug, regulation of DNA-templated transcription, signal transduction, skin development, smoothened signaling pathway, smoothened signaling pathway involved in spinal cord motor neuron cell fate specification, smoothened signaling pathway involved in ventral spinal cord interneuron specification, spermatid development, spinal cord dorsal/ventral patterning, spinal cord motor neuron cell fate specification, ventral spinal cord interneuron specification, ventricular septum development; MF: beta-catenin binding, protein binding, protein kinase binding, protein sequestering activity; CC: GLI-SUFU complex, cilium, cytoplasm, cytosol, nucleoplasm, nucleus
Pathways: Basal cell carcinoma - Mus musculus (mouse), Degradation of GLI1 by the proteasome, GLI3 is processed to GLI3R by the proteasome, Hedgehog 'off' state, Hedgehog 'on' state, Hedgehog signaling pathway - Mus musculus (mouse), Pathways in cancer - Mus musculus (mouse), Signal Transduction, Signaling by Hedgehog
UniProt: Q9Z0P7
Entrez ID: 24069
|
SCREEN_17_HITS_ONLY_FOR_INVERSE.tsv
|
mouse
|
knockout
|
B2m
|
3LL Lewis lung carcinoma cells
|
decreased resistance to PD1 blockade and lung carcinoma cell death
| 0
|
difficult
|
Does knockout of B2m in 3LL Lewis lung carcinoma cells causally result in decreased resistance to PD1 blockade and lung carcinoma cell death?
|
Gene: B2m (beta-2 microglobulin)
Type: protein-coding
Summary: No summary available.
Gene Ontology: BP: T cell differentiation in thymus, amyloid fibril formation, antibacterial humoral response, antigen processing and presentation of endogenous peptide antigen via MHC class I, antigen processing and presentation of exogenous peptide antigen via MHC class II, antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-dependent, antigen processing and presentation of peptide antigen via MHC class I, antimicrobial humoral immune response mediated by antimicrobial peptide, cellular defense response, cellular response to iron ion, cellular response to iron(III) ion, cellular response to lipopolysaccharide, cellular response to nicotine, defense response to Gram-negative bacterium, defense response to Gram-positive bacterium, immune response, immune system process, innate immune response, intracellular iron ion homeostasis, iron ion transport, learning or memory, multicellular organismal-level iron ion homeostasis, negative regulation of epithelial cell proliferation, negative regulation of forebrain neuron differentiation, negative regulation of iron ion transport, negative regulation of neurogenesis, negative regulation of neuron projection development, negative regulation of receptor-mediated endocytosis, peptide antigen assembly with MHC class I protein complex, peptide antigen assembly with MHC class II protein complex, positive regulation of T cell activation, positive regulation of T cell cytokine production, positive regulation of T cell mediated cytotoxicity, positive regulation of cellular senescence, positive regulation of immune response, positive regulation of receptor-mediated endocytosis, protein homotetramerization, protein refolding, regulation of erythrocyte differentiation, regulation of iron ion transport, regulation of membrane depolarization, response to metal ion, response to molecule of bacterial origin, sensory perception of smell, transferrin transport; MF: MHC class II protein complex binding, identical protein binding, peptide antigen binding, protein binding, protein homodimerization activity, structural molecule activity; CC: Golgi apparatus, HFE-transferrin receptor complex, MHC class I peptide loading complex, MHC class I protein complex, MHC class II protein complex, cytosol, external side of plasma membrane, extracellular region, extracellular space, late endosome membrane, lysosomal membrane, phagocytic vesicle membrane, plasma membrane
Pathways: Adaptive Immune System, Antigen Presentation: Folding, assembly and peptide loading of class I MHC, Antigen processing and presentation - Mus musculus (mouse), Antigen processing-Cross presentation, Class I MHC mediated antigen processing & presentation, DAP12 interactions, DAP12 signaling, ER-Phagosome pathway, Endosomal/Vacuolar pathway, Epstein-Barr virus infection - Mus musculus (mouse), Herpes simplex virus 1 infection - Mus musculus (mouse), Human T-cell leukemia virus 1 infection - Mus musculus (mouse), Human cytomegalovirus infection - Mus musculus (mouse), Human immunodeficiency virus 1 infection - Mus musculus (mouse), Immune System, Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell, Innate Immune System, Neutrophil degranulation
UniProt: P01887
Entrez ID: 12010
|
SCREEN_17_HITS_ONLY_FOR_INVERSE.tsv
|
mouse
|
knockout
|
Stat1
|
3LL Lewis lung carcinoma cells
|
decreased resistance to PD1 blockade and lung carcinoma cell death
| 0
|
difficult
|
Does knockout of Stat1 in 3LL Lewis lung carcinoma cells causally result in decreased resistance to PD1 blockade and lung carcinoma cell death?
|
Gene: Stat1 (signal transducer and activator of transcription 1)
Type: protein-coding
Summary: No summary available.
Gene Ontology: BP: DNA-templated transcription, blood circulation, cell population proliferation, cell surface receptor signaling pathway via JAK-STAT, cell surface receptor signaling pathway via STAT, cellular response to cytokine stimulus, cellular response to interferon-beta, cellular response to lipopolysaccharide, cellular response to type II interferon, cytokine-mediated signaling pathway, defense response, defense response to virus, interleukin-27-mediated signaling pathway, interleukin-7-mediated signaling pathway, interleukin-9-mediated signaling pathway, lipopolysaccharide-mediated signaling pathway, metanephric mesenchymal cell differentiation, metanephric mesenchymal cell proliferation involved in metanephros development, negative regulation by virus of viral protein levels in host cell, negative regulation of angiogenesis, negative regulation of canonical NF-kappaB signal transduction, negative regulation of developmental process, negative regulation of endothelial cell proliferation, negative regulation of macrophage fusion, negative regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis, negative regulation of metanephric nephron tubule epithelial cell differentiation, negative regulation of transcription by RNA polymerase II, positive regulation of DNA-templated transcription, positive regulation of apoptotic process, positive regulation of defense response to virus by host, positive regulation of erythrocyte differentiation, positive regulation of interferon-alpha production, positive regulation of mesenchymal cell proliferation, positive regulation of receptor signaling pathway via JAK-STAT, positive regulation of smooth muscle cell proliferation, positive regulation of transcription by RNA polymerase II, regulation of DNA-templated transcription, regulation of apoptotic process, regulation of cell population proliferation, regulation of transcription by RNA polymerase II, renal tubule development, response to bacterium, response to cAMP, response to cytokine, response to exogenous dsRNA, response to interferon-beta, response to lipopolysaccharide, response to peptide hormone, response to type I interferon, response to type II interferon, signal transduction, tumor necrosis factor-mediated signaling pathway, type I interferon-mediated signaling pathway, type II interferon-mediated signaling pathway; MF: CCR5 chemokine receptor binding, DNA binding, DNA-binding transcription factor activity, DNA-binding transcription factor activity, RNA polymerase II-specific, RNA polymerase II cis-regulatory region sequence-specific DNA binding, RNA polymerase II core promoter sequence-specific DNA binding, RNA polymerase II transcription regulatory region sequence-specific DNA binding, double-stranded DNA binding, enzyme binding, histone acetyltransferase binding, histone binding, identical protein binding, promoter-specific chromatin binding, protein binding, protein homodimerization activity, protein phosphatase 2A binding, sequence-specific DNA binding, transcription coactivator binding, transcription corepressor binding, tumor necrosis factor receptor binding, ubiquitin-like protein ligase binding; CC: ISGF3 complex, RNA polymerase II transcription regulator complex, axon, chromatin, cytoplasm, cytosol, dendrite, nucleolus, nucleoplasm, nucleus, perinuclear region of cytoplasm, protein-containing complex
Pathways: AGE-RAGE signaling pathway in diabetic complications - Mus musculus (mouse), C-type lectin receptor signaling pathway - Mus musculus (mouse), Chemokine signaling pathway - Mus musculus (mouse), Coronavirus disease - COVID-19 - Mus musculus (mouse), Epstein-Barr virus infection - Mus musculus (mouse), Growth hormone synthesis, secretion and action - Mus musculus (mouse), Hepatitis B - Mus musculus (mouse), Hepatitis C - Mus musculus (mouse), Herpes simplex virus 1 infection - Mus musculus (mouse), Human papillomavirus infection - Mus musculus (mouse), Inflammatory bowel disease - Mus musculus (mouse), Influenza A - Mus musculus (mouse), JAK-STAT signaling pathway - Mus musculus (mouse), Kaposi sarcoma-associated herpesvirus infection - Mus musculus (mouse), Leishmaniasis - Mus musculus (mouse), Measles - Mus musculus (mouse), NOD-like receptor signaling pathway - Mus musculus (mouse), Necroptosis - Mus musculus (mouse), Osteoclast differentiation - Mus musculus (mouse), PD-L1 expression and PD-1 checkpoint pathway in cancer - Mus musculus (mouse), Pancreatic cancer - Mus musculus (mouse), Pathways in cancer - Mus musculus (mouse), Prolactin signaling pathway - Mus musculus (mouse), Th1 and Th2 cell differentiation - Mus musculus (mouse), Th17 cell differentiation - Mus musculus (mouse), Thyroid hormone signaling pathway - Mus musculus (mouse), Toll-like receptor signaling pathway - Mus musculus (mouse), Toxoplasmosis - Mus musculus (mouse), Tuberculosis - Mus musculus (mouse)
UniProt: Q8C3V4, Q99K94, Q8CFQ1, Q8C8M3, Q8C497, A0A087WSP5, A0A087WRI1, A0A087WSQ5
Entrez ID: 20846
|
SCREEN_17_HITS_ONLY_FOR_INVERSE.tsv
|
mouse
|
knockout
|
Tbk1
|
3LL Lewis lung carcinoma cells
|
decreased resistance to PD1 blockade and lung carcinoma cell death
| 0
|
difficult
|
Does knockout of Tbk1 in 3LL Lewis lung carcinoma cells causally result in decreased resistance to PD1 blockade and lung carcinoma cell death?
|
Gene: Tbk1 (TANK-binding kinase 1)
Type: protein-coding
Summary: No summary available.
Gene Ontology: BP: T follicular helper cell differentiation, TORC1 signaling, TORC2 signaling, activation of innate immune response, antiviral innate immune response, cGAS/STING signaling pathway, cellular response to nutrient levels, cytoplasmic pattern recognition receptor signaling pathway, cytoplasmic translation, defense response to Gram-positive bacterium, defense response to other organism, defense response to virus, dendritic cell proliferation, immune system process, innate immune response, mRNA transcription, negative regulation of TORC1 signaling, negative regulation of gene expression, peptidyl-serine phosphorylation, peptidyl-threonine phosphorylation, phosphatidylinositol 3-kinase/protein kinase B signal transduction, positive regulation of TOR signaling, positive regulation of TORC1 signaling, positive regulation of TORC2 signaling, positive regulation of autophagy, positive regulation of canonical NF-kappaB signal transduction, positive regulation of interferon-alpha production, positive regulation of interferon-beta production, positive regulation of macroautophagy, positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction, positive regulation of transcription by RNA polymerase II, positive regulation of translational initiation, positive regulation of type I interferon production, positive regulation of type I interferon-mediated signaling pathway, positive regulation of xenophagy, protein import into nucleus, protein phosphorylation, regulation of gene expression, regulation of type I interferon production, toll-like receptor 4 signaling pathway; MF: ATP binding, RNA polymerase II-specific DNA-binding transcription factor binding, identical protein binding, kinase activity, nucleic acid binding, nucleotide binding, phosphoprotein binding, protein binding, protein kinase activity, protein phosphatase binding, protein serine kinase activity, protein serine/threonine kinase activity, transferase activity; CC: cytoplasm, cytosol, nucleoplasm
Pathways: Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE), Alcoholic liver disease - Mus musculus (mouse), Amyotrophic lateral sclerosis - Mus musculus (mouse), Autophagy, Autophagy - animal - Mus musculus (mouse), Coronavirus disease - COVID-19 - Mus musculus (mouse), Cytokine Signaling in Immune system, Cytosolic DNA-sensing pathway - Mus musculus (mouse), Cytosolic sensors of pathogen-associated DNA , DDX58/IFIH1-mediated induction of interferon-alpha/beta, Death Receptor Signaling, Epstein-Barr virus infection - Mus musculus (mouse), Hepatitis B - Mus musculus (mouse), Hepatitis C - Mus musculus (mouse), Herpes simplex virus 1 infection - Mus musculus (mouse), Human cytomegalovirus infection - Mus musculus (mouse), Human immunodeficiency virus 1 infection - Mus musculus (mouse), Human papillomavirus infection - Mus musculus (mouse), IL-17 signaling pathway - Mus musculus (mouse), IRF3-mediated induction of type I IFN, Immune System, Influenza A - Mus musculus (mouse), Innate Immune System, Interleukin-1 family signaling, Interleukin-37 signaling, Kaposi sarcoma-associated herpesvirus infection - Mus musculus (mouse), Lipid and atherosclerosis - Mus musculus (mouse), Macroautophagy, Measles - Mus musculus (mouse), Mitophagy, Mitophagy - animal - Mus musculus (mouse), MyD88-independent TLR4 cascade , NOD-like receptor signaling pathway - Mus musculus (mouse), Negative regulators of DDX58/IFIH1 signaling, PINK1-PRKN Mediated Mitophagy, Pathways of neurodegeneration - multiple diseases - Mus musculus (mouse), RIG-I-like receptor signaling pathway - Mus musculus (mouse), Ras signaling pathway - Mus musculus (mouse), Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 , Regulation of TNFR1 signaling, Regulation of innate immune responses to cytosolic DNA, STAT6-mediated induction of chemokines, STING mediated induction of host immune responses, Selective autophagy, Signal Transduction, Signaling by Interleukins, TNF signaling, TNFR1-induced proapoptotic signaling, TRIF (TICAM1)-mediated TLR4 signaling , Toll Like Receptor 4 (TLR4) Cascade, Toll-like Receptor Cascades, Toll-like receptor signaling pathway - Mus musculus (mouse), Yersinia infection - Mus musculus (mouse)
UniProt: Q9WUN2
Entrez ID: 56480
|
SCREEN_17_HITS_ONLY_FOR_INVERSE.tsv
|
mouse
|
knockout
|
Jak1
|
3LL Lewis lung carcinoma cells
|
decreased resistance to PD1 blockade and lung carcinoma cell death
| 0
|
difficult
|
Does knockout of Jak1 in 3LL Lewis lung carcinoma cells causally result in decreased resistance to PD1 blockade and lung carcinoma cell death?
|
Gene: Jak1 (Janus kinase 1)
Type: protein-coding
Summary: No summary available.
Gene Ontology: BP: cell differentiation, cell surface receptor signaling pathway via JAK-STAT, cellular response to interleukin-3, cellular response to interleukin-7, cytokine-mediated signaling pathway, enzyme-linked receptor protein signaling pathway, growth hormone receptor signaling pathway via JAK-STAT, interleukin-10-mediated signaling pathway, interleukin-11-mediated signaling pathway, interleukin-15-mediated signaling pathway, interleukin-2-mediated signaling pathway, interleukin-4-mediated signaling pathway, interleukin-6-mediated signaling pathway, interleukin-7-mediated signaling pathway, interleukin-9-mediated signaling pathway, intracellular signal transduction, positive regulation of homotypic cell-cell adhesion, positive regulation of protein localization to nucleus, positive regulation of receptor signaling pathway via STAT, positive regulation of sprouting angiogenesis, protein localization to cell-cell junction, regulation of transcription by RNA polymerase II, response to antibiotic, type I interferon-mediated signaling pathway, type II interferon-mediated signaling pathway; MF: ATP binding, CCR5 chemokine receptor binding, growth hormone receptor binding, kinase activity, metal ion binding, non-membrane spanning protein tyrosine kinase activity, nucleotide binding, protein binding, protein kinase activity, protein phosphatase binding, protein tyrosine kinase activity, transferase activity, ubiquitin protein ligase binding; CC: cytoplasm, cytoplasmic side of plasma membrane, cytosol, endomembrane system, extrinsic component of cytoplasmic side of plasma membrane, membrane, nucleus, receptor complex
Pathways: Coronavirus disease - COVID-19 - Mus musculus (mouse), Epstein-Barr virus infection - Mus musculus (mouse), Hepatitis B - Mus musculus (mouse), Hepatitis C - Mus musculus (mouse), Herpes simplex virus 1 infection - Mus musculus (mouse), Human T-cell leukemia virus 1 infection - Mus musculus (mouse), Human cytomegalovirus infection - Mus musculus (mouse), Human papillomavirus infection - Mus musculus (mouse), Influenza A - Mus musculus (mouse), JAK-STAT signaling pathway - Mus musculus (mouse), Kaposi sarcoma-associated herpesvirus infection - Mus musculus (mouse), Leishmaniasis - Mus musculus (mouse), Measles - Mus musculus (mouse), NOD-like receptor signaling pathway - Mus musculus (mouse), Necroptosis - Mus musculus (mouse), Osteoclast differentiation - Mus musculus (mouse), PD-L1 expression and PD-1 checkpoint pathway in cancer - Mus musculus (mouse), PI3K-Akt signaling pathway - Mus musculus (mouse), Pancreatic cancer - Mus musculus (mouse), Pathways in cancer - Mus musculus (mouse), Signaling pathways regulating pluripotency of stem cells - Mus musculus (mouse), Th1 and Th2 cell differentiation - Mus musculus (mouse), Th17 cell differentiation - Mus musculus (mouse), Toxoplasmosis - Mus musculus (mouse), Tuberculosis - Mus musculus (mouse), Viral carcinogenesis - Mus musculus (mouse)
UniProt: Q3U8P8, Q3URU8, B1ASP2, B1ASP3
Entrez ID: 16451
|
SCREEN_17_HITS_ONLY_FOR_INVERSE.tsv
|
mouse
|
knockout
|
Afdn
|
3LL Lewis lung carcinoma cells
|
decreased resistance to PD1 blockade and lung carcinoma cell death
| 0
|
difficult
|
Does knockout of Afdn in 3LL Lewis lung carcinoma cells causally result in decreased resistance to PD1 blockade and lung carcinoma cell death?
|
Gene: Afdn (afadin, adherens junction formation factor)
Type: protein-coding
Summary: No summary available.
Gene Ontology: BP: adherens junction maintenance, bicellular tight junction assembly, brain morphogenesis, cell adhesion, cell differentiation, cell junction organization, cell-cell adhesion mediated by cadherin, cerebral cortex development, dendrite arborization, establishment of endothelial intestinal barrier, establishment of protein localization to plasma membrane, homeostasis of number of cells, negative regulation of cell migration, neuroepithelial cell differentiation, pore complex assembly, positive regulation of cell-cell adhesion, positive regulation of cell-cell adhesion mediated by cadherin, positive regulation of dendrite extension, positive regulation of dendrite morphogenesis, positive regulation of dendritic spine morphogenesis, positive regulation of gene expression, positive regulation of mini excitatory postsynaptic potential, postsynaptic specialization organization, protein localization to cell junction, radial glial cell differentiation, regulation of oligodendrocyte progenitor proliferation, regulation of postsynapse assembly, regulation of postsynapse organization, regulation of protein localization, signal transduction, telencephalon development; MF: LIM domain binding, actin filament binding, cell adhesion molecule binding, protein binding, small GTPase binding; CC: adherens junction, anchoring junction, apical junction complex, apical part of cell, axon, cell junction, cell-cell contact zone, cell-cell junction, cytoplasm, cytosol, excitatory synapse, glutamatergic synapse, hippocampal mossy fiber to CA3 synapse, nuclear speck, nucleoplasm, plasma membrane, pore complex, postsynaptic density membrane, presynaptic active zone membrane, somatodendritic compartment, tight junction
Pathways: Adherens junction - Mus musculus (mouse), Adherens junctions interactions, Cell junction organization, Cell-Cell communication, Cell-cell junction organization, Leukocyte transendothelial migration - Mus musculus (mouse), Rap1 signaling pathway - Mus musculus (mouse), Ras signaling pathway - Mus musculus (mouse), Tight junction - Mus musculus (mouse), cAMP signaling pathway - Mus musculus (mouse)
UniProt: Q9QZQ1
Entrez ID: 17356
|
SCREEN_17_HITS_ONLY_FOR_INVERSE.tsv
|
mouse
|
knockout
|
Fbxw7
|
3LL Lewis lung carcinoma cells
|
decreased resistance to PD1 blockade and lung carcinoma cell death
| 0
|
difficult
|
Does knockout of Fbxw7 in 3LL Lewis lung carcinoma cells causally result in decreased resistance to PD1 blockade and lung carcinoma cell death?
|
Gene: Fbxw7 (F-box and WD-40 domain protein 7)
Type: protein-coding
Summary: No summary available.
Gene Ontology: BP: DNA damage response, DNA repair, G1/S transition of mitotic cell cycle, Notch signaling pathway, SCF-dependent proteasomal ubiquitin-dependent protein catabolic process, cellular response to UV, lung development, negative regulation of Notch signaling pathway, negative regulation of gene expression, negative regulation of osteoclast development, negative regulation of proteasomal ubiquitin-dependent protein catabolic process, negative regulation of ubiquitin-dependent protein catabolic process, positive regulation of ERK1 and ERK2 cascade, positive regulation of epidermal growth factor receptor signaling pathway, positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway, positive regulation of proteasomal protein catabolic process, positive regulation of protein targeting to mitochondrion, positive regulation of protein ubiquitination, positive regulation of transcription by RNA polymerase II, positive regulation of ubiquitin-dependent protein catabolic process, proteasome-mediated ubiquitin-dependent protein catabolic process, protein K63-linked ubiquitination, protein destabilization, protein stabilization, protein ubiquitination, regulation of cell migration involved in sprouting angiogenesis, regulation of circadian rhythm, regulation of mitophagy, regulation of mitotic cell cycle, regulation of protein stability, rhythmic process, sister chromatid cohesion, ubiquitin recycling, vasculature development, vasculogenesis; MF: cyclin binding, identical protein binding, phosphothreonine residue binding, protein binding, protein-macromolecule adaptor activity, ubiquitin binding, ubiquitin protein ligase binding, ubiquitin-like ligase-substrate adaptor activity, ubiquitin-protein transferase activator activity; CC: Golgi apparatus, Parkin-FBXW7-Cul1 ubiquitin ligase complex, SCF ubiquitin ligase complex, chromosome, cytoplasm, endoplasmic reticulum, membrane, mitochondrion, nucleolus, nucleoplasm, nucleus, perinuclear region of cytoplasm, protein-containing complex
Pathways: Adaptive Immune System, Antigen processing: Ubiquitination & Proteasome degradation, Class I MHC mediated antigen processing & presentation, Immune System, Metabolism of proteins, Neddylation, Post-translational protein modification, Ubiquitin mediated proteolysis - Mus musculus (mouse)
UniProt: Q8VBV4
Entrez ID: 50754
|
SCREEN_17_HITS_ONLY_FOR_INVERSE.tsv
|
mouse
|
knockout
|
Cbfb
|
3LL Lewis lung carcinoma cells
|
decreased resistance to PD1 blockade and lung carcinoma cell death
| 1
|
difficult
|
Does knockout of Cbfb in 3LL Lewis lung carcinoma cells causally result in decreased resistance to PD1 blockade and lung carcinoma cell death?
|
Gene: Cbfb (core binding factor beta)
Type: protein-coding
Summary: No summary available.
Gene Ontology: BP: cell maturation, definitive hemopoiesis, lymphocyte differentiation, myeloid cell differentiation, negative regulation of CD4-positive, alpha-beta T cell differentiation, negative regulation of transcription by RNA polymerase II, ossification, osteoblast differentiation, positive regulation of CD8-positive, alpha-beta T cell differentiation, positive regulation of transcription by RNA polymerase II, protein polyubiquitination, regulation of transcription by RNA polymerase II; MF: DNA binding, protein binding, sequence-specific DNA binding, transcription coactivator activity; CC: core-binding factor complex, nucleoplasm, nucleus, protein-containing complex
Pathways: ESR-mediated signaling, Estrogen-dependent gene expression, Gene expression (Transcription), Generic Transcription Pathway, RNA Polymerase II Transcription, RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs), RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known, RUNX1 regulates estrogen receptor mediated transcription, RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function, RUNX1 regulates transcription of genes involved in BCR signaling, RUNX1 regulates transcription of genes involved in differentiation of HSCs, RUNX1 regulates transcription of genes involved in differentiation of myeloid cells, RUNX1 regulates transcription of genes involved in interleukin signaling, RUNX2 regulates bone development, RUNX3 regulates p14-ARF, Regulation of RUNX1 Expression and Activity, Regulation of RUNX3 expression and activity, Signal Transduction, Signaling by Nuclear Receptors, Transcriptional regulation by RUNX1, Transcriptional regulation by RUNX2, Transcriptional regulation by RUNX3
UniProt: Q08024
Entrez ID: 12400
|
SCREEN_17_HITS_ONLY_FOR_INVERSE.tsv
|
mouse
|
knockout
|
Ptpn2
|
3LL Lewis lung carcinoma cells
|
decreased resistance to PD1 blockade and lung carcinoma cell death
| 1
|
difficult
|
Does knockout of Ptpn2 in 3LL Lewis lung carcinoma cells causally result in decreased resistance to PD1 blockade and lung carcinoma cell death?
|
Gene: Ptpn2 (protein tyrosine phosphatase, non-receptor type 2)
Type: protein-coding
Summary: No summary available.
Gene Ontology: BP: B cell differentiation, T cell differentiation, erythrocyte differentiation, glucose homeostasis, insulin receptor recycling, insulin receptor signaling pathway, negative regulation of ERK1 and ERK2 cascade, negative regulation of T cell receptor signaling pathway, negative regulation of cell population proliferation, negative regulation of chemotaxis, negative regulation of epidermal growth factor receptor signaling pathway, negative regulation of inflammatory response, negative regulation of insulin receptor signaling pathway, negative regulation of interleukin-2-mediated signaling pathway, negative regulation of interleukin-4-mediated signaling pathway, negative regulation of interleukin-6-mediated signaling pathway, negative regulation of lipid storage, negative regulation of macrophage colony-stimulating factor signaling pathway, negative regulation of macrophage differentiation, negative regulation of platelet-derived growth factor receptor-beta signaling pathway, negative regulation of positive thymic T cell selection, negative regulation of receptor signaling pathway via JAK-STAT, negative regulation of transcription by RNA polymerase II, negative regulation of tumor necrosis factor-mediated signaling pathway, negative regulation of type I interferon-mediated signaling pathway, negative regulation of type II interferon-mediated signaling pathway, negative regulation of tyrosine phosphorylation of STAT protein, peptidyl-tyrosine dephosphorylation, positive regulation of PERK-mediated unfolded protein response, positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway, positive regulation of gluconeogenesis, regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway, regulation of hepatocyte growth factor receptor signaling pathway; MF: STAT family protein binding, hydrolase activity, integrin binding, non-membrane spanning protein tyrosine phosphatase activity, phosphoprotein phosphatase activity, protein binding, protein kinase binding, protein tyrosine phosphatase activity, receptor tyrosine kinase binding, syntaxin binding; CC: cytoplasm, cytosol, endoplasmic reticulum, endoplasmic reticulum-Golgi intermediate compartment, endosome lumen, membrane, nucleoplasm, nucleus, plasma membrane
Pathways: Antiviral mechanism by IFN-stimulated genes, Cytokine Signaling in Immune system, Immune System, Interferon Signaling, Interferon gamma signaling, JAK-STAT signaling pathway - Mus musculus (mouse), Negative regulation of MET activity, PKR-mediated signaling, Regulation of IFNG signaling, Signal Transduction, Signaling by MET, Signaling by Receptor Tyrosine Kinases
UniProt: Q06180
Entrez ID: 19255
|
SCREEN_17_HITS_ONLY_FOR_INVERSE.tsv
|
mouse
|
knockout
|
Rpl18
|
3LL Lewis lung carcinoma cells
|
decreased resistance to PD1 blockade and lung carcinoma cell death
| 1
|
difficult
|
Does knockout of Rpl18 in 3LL Lewis lung carcinoma cells causally result in decreased resistance to PD1 blockade and lung carcinoma cell death?
|
Gene: Rpl18 (ribosomal protein L18)
Type: protein-coding
Summary: No summary available.
Gene Ontology: BP: cytoplasmic translation, translation; MF: RNA binding, structural constituent of ribosome; CC: cytoplasm, cytosol, cytosolic large ribosomal subunit, cytosolic ribosome, endoplasmic reticulum, nucleolus, ribonucleoprotein complex, ribosome, rough endoplasmic reticulum, synapse
Pathways: Cap-dependent Translation Initiation, Coronavirus disease - COVID-19 - Mus musculus (mouse), Eukaryotic Translation Initiation, Formation of a pool of free 40S subunits, GTP hydrolysis and joining of the 60S ribosomal subunit, L13a-mediated translational silencing of Ceruloplasmin expression, Major pathway of rRNA processing in the nucleolus and cytosol, Metabolism of RNA, Metabolism of proteins, Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC), Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC), Nonsense-Mediated Decay (NMD), PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA, Ribosome - Mus musculus (mouse), Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide, Ribosome-associated quality control, SRP-dependent cotranslational protein targeting to membrane, Translation, ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA, rRNA processing, rRNA processing in the nucleus and cytosol
UniProt: P35980
Entrez ID: 19899
|
BIOGRID-1837.tsv
| null |
activation
|
CD28
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of CD28 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
VAV1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of VAV1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
CNR2
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of CNR2 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
OTUD7B
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of OTUD7B in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
DEF6
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of DEF6 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
DEPDC7
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of DEPDC7 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
FOXD2
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of FOXD2 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
HSFX2
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of HSFX2 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
OR2T2
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of OR2T2 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
GPR84
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of GPR84 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
LCP2
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of LCP2 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
TNFRSF9
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of TNFRSF9 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
SLC16A1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of SLC16A1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
MAP2K6
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of MAP2K6 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
PIK3AP1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of PIK3AP1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
TBX21
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of TBX21 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
P2RY14
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of P2RY14 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
ZAP70
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of ZAP70 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
PLCG2
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of PLCG2 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
IRX4
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of IRX4 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
SQSTM1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of SQSTM1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
OTUD7A
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of OTUD7A in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
FOXQ1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of FOXQ1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
SERINC3
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of SERINC3 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
RRAS2
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of RRAS2 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
GPR18
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of GPR18 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
TAB3
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of TAB3 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
FOXD1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of FOXD1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
RER1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of RER1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
RAC2
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of RAC2 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
RUNX3
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of RUNX3 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
VAV3
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of VAV3 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
PLEKHG6
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of PLEKHG6 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
GEMIN7
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of GEMIN7 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
IL36A
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of IL36A in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
LIN9
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of LIN9 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
EMP1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of EMP1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
ELAVL3
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of ELAVL3 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
ZDHHC2
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of ZDHHC2 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
PIK3R6
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of PIK3R6 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
RELA
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of RELA in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
SFN
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of SFN in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
GPR20
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of GPR20 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
ABHD6
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of ABHD6 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
TNFRSF1A
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of TNFRSF1A in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
CD40
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of CD40 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
FAM129B
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of FAM129B in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
TF
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of TF in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
WIPF1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of WIPF1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
AKT3
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of AKT3 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
PPIL3
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of PPIL3 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
GPR141
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of GPR141 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
MYRF
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of MYRF in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
PLAA
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of PLAA in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
HCAR2
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of HCAR2 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
TRAF3IP2
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of TRAF3IP2 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
MAP3K8
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of MAP3K8 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
HEPHL1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of HEPHL1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
AKT1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of AKT1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
SWAP70
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of SWAP70 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
ZNF296
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of ZNF296 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
PKIB
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of PKIB in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
FAM92A
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of FAM92A in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
RAB3IL1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of RAB3IL1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
EIF4H
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of EIF4H in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
RHOG
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of RHOG in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
HNRNPA1L2
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of HNRNPA1L2 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
KSR2
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of KSR2 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
CUL1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of CUL1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
ABCA1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of ABCA1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
C16orf74
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of C16orf74 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
PRKCB
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of PRKCB in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
SIGLEC1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of SIGLEC1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
HLA-DQB1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of HLA-DQB1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
SERTM1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of SERTM1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
DBP
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of DBP in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
DOLPP1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of DOLPP1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
SCGB1D1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of SCGB1D1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
EDAR
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of EDAR in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
MALT1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of MALT1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
TPGS2
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of TPGS2 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
RASGRP1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of RASGRP1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
OSTM1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of OSTM1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
RPAP1
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of RPAP1 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
OLIG3
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of OLIG3 in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
BIOGRID-1837.tsv
| null |
activation
|
FAM129A
|
primary CD4+ human T cells
|
increased TNF-alpha secretion
| 1
|
simple
|
Does activation of FAM129A in primary CD4+ human T cells causally result in increased TNF-alpha secretion?
| null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.